| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
The Leeds Institute of Genetics, Health and Therapeutics (E.W.H.), The University of Leeds, Leeds LS2 9NL, United Kingdom; and Department of Endocrinology and Metabolism (D.K.G.), Warwick Medical School, The University of Warwick, Coventry CV4 7AL, United Kingdom
Correspondence: Address all correspondence and requests for reprints to: Edward W. Hillhouse, The Leeds Institute of Genetics, Health and Therapeutics, The University of Leeds, Leeds LS2 9NL, United Kingdom. E-mail: e.w.hillhouse{at}leeds.ac.uk; or Dimitris K. Grammatopoulos, Endocrinology and Metabolism, Warwick Medical School, The University of Warwick, Coventry CV4 7AL, United Kingdom. E-mail: d.grammatopoulos{at}warwick.ac.uk.
 |
Abstract |
|---|
 Top Abstract I. IntroductionII. CRH-R Agonists: the...III. CRH-R SubfamiliesIV. Agonist-CRH-R InteractionV. CRH-R Signaling...VI. Regulation of CRH-R...VII. ConclusionsReferences |
|---|
|
I. Introduction |
|---|
|
TopAbstractI. IntroductionII. CRH-R Agonists: the...III. CRH-R SubfamiliesIV. Agonist-CRH-R InteractionV. CRH-R Signaling...VI. Regulation of CRH-R...VII. ConclusionsReferences |
|---|
CRH and the UCNs are expressed in multiple sites in the periphery, where they influence physiological mechanisms via paracrine or autocrine activation of specific receptors expressed on the cell membrane of target cells. These CRH receptors (CRH-Rs) and the mechanisms regulating their activity play a crucial role in mediating the biological effects of the CRH family of peptides. This review will discuss current knowledge relating to the structure, biological function, and molecular mechanisms regulating CRH-R expression and activity.
|
II. CRH-R Agonists: the Family of CRH-Related Peptides |
|---|
|
TopAbstractI. IntroductionII. CRH-R Agonists: the...III. CRH-R SubfamiliesIV. Agonist-CRH-R InteractionV. CRH-R Signaling...VI. Regulation of CRH-R...VII. ConclusionsReferences |
|---|
CRH, a 41-amino acid peptide, is the principal regulator of the basal and stress-induced pituitary-adrenal axis that activates glucocorticoid and adrenal androgen secretion (7, 8). It displays anxiogenic properties and coordinates the adaptive, behavioral, and physical changes that occur during stress; this has been conclusively demonstrated in transgenic or knockout mouse models (9, 10). Some of these actions of CRH may be mediated via the activation of norepinephrine-secreting neurons and other neurotransmitter systems important for mood regulation (11, 12, 13, 14). CRH also influences appetite via its anorexic properties (15, 16). In addition, CRH is synthesized and produced in multiple peripheral tissues and might be involved in many other biological functions, such as energy balance, metabolism, and regulation of the immune response (17, 18). Interestingly CRH also plays a role in mammalian reproduction and embryo implantation (19). It is synthesized and secreted by the human placenta and might act as a "placental clock" that regulates the onset of human labor, perhaps by modulating myometrial contractility (20, 21). Increased or chronic secretion of CRH leads to anxiety, sleep pattern disturbance, and changes in the cardiovascular, metabolic, and immune functions. CRH has been implicated in the pathophysiology of various disorders; in particular, there is good evidence linking CRH system abnormalities to chronic anxiety disorder, melancholic and atypical depression, chronic pain and fatigue states, sleep disorders, addictive behavior, neurodegeneration, allergic and autoimmune inflammatory disorders, the metabolic syndrome, and gastrointestinal diseases (22, 23, 24, 25, 26, 27).
The UCNs exhibit various degrees of amino acid sequence homology to CRH: UCN-II shows moderate identity with human/rat CRH (h/rCRH) (34%), human UCN-I (43%), and UCN-III (37–40%), whereas UCN-III displays less homology to other members of the CRH family (18–32% identity). They are also expressed in the CNS and peripheral tissues; however, their actions are less well characterized. In the brain, UCN-I expression is most prominent in the Edinger-Westphal nucleus and the lateral superior olive. There is very little neuroanatomical overlap in the distribution of UCN-I and CRH in the brain, suggesting differential functional roles for these peptides (28). UCN-I mRNA or immunoreactivity has also been reported in other brain regions including the cerebellum, hippocampus, neocortex, olfactory system, basal ganglia, amygdala, and the supraoptic, ventromedial (VMH), and paraventricular (PVN) nuclei of the hypothalamus, as well as the laterodorsal tegmental nucleus, the dorsal raphe, the periaqueductal gray, the substantia nigra pars compacta, and ventral tegmental nucleus. In the latter two regions, UCN-I immunoreactivity is located almost exclusively in neurons that coexpress tyrosine hydroxylase, suggesting that within these regions, UCN-I is colocalized with dopamine. Interestingly, several brain regions such as the ventromedial hypothalamus and the amygdala (tissues rich in CRH-R2 receptors that exhibit significant selectivity for the UCNs; see Section III.A) do not contain UCN-I immunoreactive fibers. UCN-I expression has also been demonstrated in peripheral tissues such as the heart, adrenal, skeletal muscle, placenta, skin, immune system, and the gastrointestinal tract (29).
A similar pattern of distribution to that of UCN-I was found for UCN-II mRNA in the mouse and rat CNS (29). UCN-II mRNA is highly expressed in the paraventricular, supraoptic, and arcuate nuclei of the hypothalamus, the locus coeruleus, and motor nuclei of the brain stem and spinal cord. The posterior part of the bed nucleus of the stria terminalis, the lateral septum, and the medial amygdaloid nucleus are important brain sites that express UCN-II mRNA. Histologically, UCN-II mRNA and UCN-II-like immunoreactivity were demonstrated in both the anterior and intermediate lobes of the pituitary, but not detected in the posterior lobe. In the periphery, high levels of UCN-II mRNA have been detected in the heart, adrenal gland, placenta, stomach, skin, ovary, gastrointestinal tract, uterus, uterine smooth and skeletal muscle, and peripheral blood cells (29).
UCN-III displays a distinct distribution from that of CRH, UCN-I, and UCN-II (30). UCN-III-positive neurons were found predominately within the hypothalamus and medial amygdala. In the hypothalamus, UCN-III neurons were observed in the median preoptic nucleus and in the rostral perifornical area lateral to the PVN. The UCN-III fibers were distributed mainly in the hypothalamus and limbic structures. Hypothalamic regions that were innervated prominently by UCN-III fibers included the ventromedial nucleus, medial preoptic nucleus, and ventral premammillary nucleus. Outside the hypothalamus, the densest projections were found in the intermediate part of the lateral septum, posterior division of the bed nucleus stria terminalis, and the medial nucleus of the amygdala. Several major UCN-III terminal fields have been identified, including the lateral septum and the ventromedial hypothalamus, which are known to express high levels of CRH-R2. Thus, these anatomical data strongly support the notion that UCN-III is an endogenous ligand for CRH-R2 in these areas. These results also suggest that UCN-III is likely to mediate physiological functions, including food intake and neuroendocrine regulation (30). In the periphery, immunoreactive UCN-III is expressed in the human adrenals (31), heart, and kidney, particularly the distal tubules (32).
Animal studies using UCN-I-knockout mice suggest that UCN-I might not play a critical role in the HPA axis response to stress or in stress-induced autonomic control (33). However, when administered into the brain via the ventricles, UCN-I displays anorectic and anxiogenic properties similar to CRH. The UCNs are differentially distributed in the brain and periphery and appear to be involved in a rapidly expanding array of physiological mechanisms, particularly with respect to the appetite control and cardiovascular system, where they influence vascularization and angiogenesis (34, 35, 36).
An important component of the CRH/UCNs circuits appears to be a 37-kDa circulating protein capable of binding CRH and UCN-I, the CRH binding protein (CRH-BP) (37). In rodents, CRH-BP mRNA is expressed in the pituitary and the brain, especially the cerebral cortex, amygdala, bed nucleus of the stria terminalis, raphe nuclei, brainstem reticular formation, and olfactory, auditory, trigeminal, and vestibular sensory relay systems. Some of these sites also contain CRH and UCN-I-producing neurons or CRH/UCN target cells, such as the anterior pituitary corticotrophs. In humans, CRH-BP expression has been detected in brain, pituitary, liver, and placenta (38, 39, 40). The sites of overlapping expression of CRH-BP with CRH and UCN-I suggest that CRH-BP might modulate the synaptic or endocrine actions of CRH and/or UCN-I in the CNS and the pituitary. The biochemical properties of CRH-BP are well characterized; CRH-BP binds 40–90% of the total CRH, and CRH-BP levels are approximately 10-fold higher than CRH levels in most human brain regions (41). Despite this, the role of CRH-BP in health and disease remains unknown. What is known, however, is that CRH-BP blocks CRH-mediated ACTH secretion from anterior pituitary cultures (41, 42), suggesting that endogenous CRH-BP may act as a negative regulator of CRH in vivo, possibly playing a role in CRH clearance or degradation. This is supported by studies on transgenic mice, in which the response to constitutively elevated pituitary CRH-BP levels is a compensatory elevation of hypothalamic CRH and vasopressin, to maintain homeostasis in the HPA axis (43). In contrast, CRH-BP-deficient mice exhibit normal HPA axis function (44).
|
III. CRH-R Subfamilies |
|---|
|
TopAbstractI. IntroductionII. CRH-R Agonists: the...III. CRH-R SubfamiliesIV. Agonist-CRH-R InteractionV. CRH-R Signaling...VI. Regulation of CRH-R...VII. ConclusionsReferences |
|---|
The family of GPCRs is the largest single family of integral membrane proteins. Both CRH-R1 and CRH-R2 belong to the class B1 subfamily of GPCRs ("brain-gut" neuropeptide receptors). These receptors are encoded by 15 genes in humans, and the ligands for these receptors are polypeptide hormones of 27- to 141-amino acid residues. Structurally, CRH-R1 and CRH-R2 are approximately 70% identical at the amino acid level, but exhibit considerable divergence at the N terminus, consistent with their distinct pharmacological properties (see Section IV.A).
CRH-Rs are also found in nonmammalian vertebrate species. Studies on nonmammalian species (for review, see Ref. 52) have identified two receptor homologs closely related to the mammalian CRH-R1 and CRH-R2, from Xenopus laevis and chun salmon (Oncorhynchus keta). Studies of the puffer fish genome showed that Fugu rubripes also encodes two CRH-R homologs with significant similarity to human CRH-R1 and -R2, respectively. Unlike all other species studied, the Ameiurus catfish encodes two distinct mammalian CRH-R1 homologs and a single R2 ortholog. Thus, there has been extensive conservation in the expression of the two types of CRH-Rs in select organs during evolution. The two CRH-R1 homologs found in catfish showed greater similarity to each other than to the CRH-R2 homolog; therefore it is possible that the two catfish CRH-R1-like genes are likely derived from further gene duplication of the ancestral CRH-R1 gene. The CRH family of peptides exhibits significant sequence identity as well as primary- and secondary-structure similarity with the diuretic hormones in insects (53). These hormone peptides are essential for the regulation of fluid secretion by Malpighian tubules in insects. Their actions are also mediated via GPCRs homologous to the mammalian CRH-Rs. Functional studies suggest that CRH-related peptides coevolved with their GPCRs during the evolution of vertebrates and insects (53). Recent genomic analysis shows that both the mosquito (Anopheles gambiae) and fruit fly (Drosophila melanogaster) genomes encode orthologs of the diuretic hormone and diuretic hormone receptors. The two D. melanogaster diuretic hormone receptors showed 51 and 57% similarity to CRH-R1 and CRH-R2, respectively (54). These data provide us with a clear evolutionary trail for the origin of the CRH/CRH-R signaling system from invertebrates to vertebrates. Based on the concept that receptors and their agonists coevolved during evolution and that the evolution of most cell surface receptors in humans can be traced to invertebrates, it is likely that the ancestors of the diuretic hormone and diuretic hormone receptors coevolved and gave rise to diuretic hormone/diuretic hormone receptor signaling in insects and CRH/CRH-R signaling in vertebrates. The latter might have originated as a paracrine signaling system important for osmoregulation. However, during early evolution of vertebrates, the ancestor CRH/CRH-R signaling pathway assumed additional functions that included the regulation of stress responses toward various environmental factors. The presence of multiple highly conserved CRH-like peptides and receptors in vertebrates suggests that gene duplication and the subsequent divergence of the regulatory mechanism of these paralogous genes provided an advantage during vertebrate evolution. Interestingly, CRH has been shown to regulate metamorphosis in response to pond drying in some amphibian species. This is consistent with the role of CRH family peptides as osmoregulators and as a stress transducer between the environment and the physiological responses of an organism. Therefore, the CRH family of peptides and their receptors are phylogenetically ancient developmental signaling molecules that allow developing organisms to coordinate physiological responses to a changing environment.
A. Distribution of CRH-R
CRH-R1 mRNA is widely expressed in mammalian brain and pituitary and is responsible for activation of the POMC gene and ACTH and ß-endorphin release from the anterior pituitary. High levels of CRH-R1 are found in the cerebral cortex, cerebellum, amygdala, hippocampus, and olfactory bulb (55). In human peripheral tissues, CRH-R1 is expressed in a wide range of tissues such as the testis, ovary, endometrium, myometrium, placenta, adrenal, adipose tissue, skin, spleen, heart, and specific cells of the immune system (55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66). CRH-R2 mRNA is expressed in a discrete pattern in the brain, with highest densities in the lateral septal nucleus, bed nucleus of stria terminalis, VMH nucleus, olfactory bulb, and mesencephalic raphe nuclei (55). In addition, CRH-R2 is also widely expressed in peripheral tissues, with high levels in the skin and skeletal, smooth, and cardiac muscle (67, 68).
The distribution of CRH-R1 and CRH-R2 in the CNS and periphery is distinct and suggests diverse physiological functions, as implied by the phenotypes of the CRH-R1 or CRH-R2 knockout mice. Interestingly, mice deficient in CRH-R1 display decreased anxiety-like behavior and have an impaired stress response (69, 70), whereas CRH-R2 mutant mice have increased anxiety-like behavior, an accelerated HPA response to stress, and impaired cardiovascular function (71, 72, 73). Paradoxically, however, the responses to administration of CRH-R2 agonists and antagonists into specific brain regions reveal both anxiolytic and anxiogenic-like roles for CRH-R2 (for review, see Ref. 74). Also, it is important to note that the expression of CRH-R1 and -R2 in the periphery exhibits important species-related differences. Most studies in animal models suggest that the CRH-R2 is the main functional receptor expressed in peripheral organs (35, 36, 76, 77). In contrast, most human peripheral tissues express both CRH-R1 and -R2, indicating a higher level of complexity and more subtle roles for CRH and UCNs in human physiology and pathophysiology. From the available data, it would seem that the expression of both CRH-R1 and CRH-R2 in human peripheral tissues allows these peptides to exert diverse and sometimes contrasting effects. Certainly CRH and the UNCs play a role in physiological processes such as energy balance and metabolism, the maintenance of cardiac function and vascular tone, gastrointestinal motor function, reproduction, pregnancy and parturition, angiogenesis, and vascularization. It seems likely that they exert their actions via the activation of CRH-R1 or CRH-R2 or both (19, 21, 77, 78, 79, 80, 81, 82, 83, 84), thus allowing CRH to fulfil its role as a stress-hormone integrating central and peripheral responses to stressful stimuli.
B. Splicing pattern and genomic organization
One of the more remarkable findings from the Human Genome Project (http://genome.wellcome.ac.uk) was the observation that human chromosomes harbor far fewer genes than were predicted. It appears that the key to the differences between humans and worms lies in the functions of some human genes and the proteins they encode. Furthermore, functional complexity is added by the use of alternative splicing of mRNA to create several distinct proteins from a single gene. Both CRH-R genes exhibit substantial similarity to the glucagon/PTH receptor (PTH-R) gene family that is characterized by the presence of introns within its TMD/cytoplasmic module, highly conserved cysteines in its extracellular domain (ECD), and a highly conserved first intracellular (IC) loop. The exon/intron junctions of the CRH, PTH, and glucagon receptor genes are remarkably similar in alignment following the signal peptide encoded by exons 1 and 2. The CRH-R1 exon/intron junctions are aligned to that of the PTH and glucagon receptors after exons 3, 5, 7, 8, 9, 10, and 12. CRH-R1 is similar to the PTH-R in that amino acids 457–509 are divided into exons 11 and 12, whereas this domain in the glucagon receptor is a single exon. The exon-intron organization of this GPCR family suggests a common evolutionary origin and, unlike other GPCR subfamilies, permits extensive alternate splicing. The evolutionary process has used this property to generate diverse receptors from a single gene, each with differing ligand specificity, binding, and G protein coupling. The fact that B1 GPCRs have multiple coding exons in comparison to other GPCR family members may be due to their being generated as an alternative to gene duplication during evolution. The increasing complexity seen within this GPCR subfamily seems to have evolved by divergence from a simpler regulated gene with increasing complexity of the organism.
1. CRH-R1.
In most mammals, the fully active CRH-R1 receptor protein arises from transcription of all 13 exons present within the CRH-R1 gene sequence. In humans, however, the genomic organization and regulatory control is different, possibly reflecting a higher level of regulation associated with species evolution. In humans, the CRH-R1 gene, which spans over 20 kb, contains 14 exons, and the complete gene product is a 444-amino acid 7 TMD protein receptor, termed CRH-R1ß, that exhibits impaired agonist-binding and signaling properties (45). Excision of exon 6, which encodes for a 29-amino acid insert in the first IC loop (IC1), from the mRNA transcript results in expression of CRH-R1
mRNA. This appears to be the main functional CRH-R1 receptor variant containing 415 amino acids, which primarily mediates CRH (and UCN-I) actions and is widely expressed throughout the body. Therefore, the CRH-R1ß can be regarded as a "pro-CRH-R1" receptor isoform, with unknown, if any, physiological function. Although lack of CRH-R1ß receptor isoform-specific antibodies has prevented the conclusive demonstration of CRH-R1ß protein expression in native cells, mRNA studies suggest that this CRH-R1 variant is expressed in the pituitary (45) as well as in peripheral tissues such as the myometrium (59), mast cells (85), endometrium (86), and heart (our unpublished data). Thus far, no tissue has been identified expressing CRH-R1ß alone, suggesting that the splicing mechanism is closely related to the mechanism regulating CRH-R1 gene expression in native tissues. One interesting feature of CRH-R1ß is that it is only expressed in humans. In rodents, the exon 6 encoding the IC loop characteristic of CRH-R1ß is absent, and, as mentioned above, the mouse and rat CRH-R1 gene contains only 13 exons (87). This suggests that the CRH-R1ß variant does not perform a crucial physiological role. This type of splicing mechanism, utilizing specific exon/intron splicing sites and excision of exons to generate multiple receptor variants, is not unique to CRH-R1, but is rather shared by other members of the B1 receptor superfamily. For example, a similar calcitonin receptor (CT-R) variant has been identified in a giant cell tumor of bone that contains a similar 16-amino acid insert in IC1 and has reduced signaling properties compared with the fully active receptor variant (88). The insert sequences in IC1 of both CRH-R1ß and CT-R "long" variant contain highly charged amino acids in their insert C termini proximal to the IC1/TMD2 junction, which might be responsible for the impaired ability to transmit signals across the cells. Just why these mRNA variants have been conserved through evolution is unknown.
The CRH-R1 gene appears to be subject to significant alternative splicing, and a growing number of CRH-R1 mRNA splice variants have been described in humans and other species. Although, as mentioned above, their physiological role is questionable, structural analysis has provided us with some useful models for studying the structural determinants of the CRH-R1 functional characteristics in comparison with other members of the B1 family of GPCRs. These variants are generated by various partial or complete exon deletions, some of which are associated with a frame-shift in the open reading frame (63, 89, 90, 92). These variants have been termed R1c-n, and all have exon 6 spliced out together with other deletions. CRH-R1c is missing exon 3, and therefore 40 amino acids are missing from the N terminus, including two regions critical for high-affinity ligand binding (see Section IV.B). Mutations in this region can affect CRH binding (93); thus, it is not surprising that expressed recombinant CRH-R1c has a decreased CRH binding capacity. CRH-R1d, which has been identified in humans and hamsters, has exon 13 (exon 12 in the rodent R1 homolog) deleted, which leads to the loss of 14 amino acids from the C-terminal end of the putative 7 TMD. This might result in either a short 7 TMD where the proximal residues of the C-tail are drawn into the membrane or a 6-TMD receptor variant containing a protein segment that fails to segregate into the membrane lipid bilayer leading to an EC C terminus, similar to the CT-R variant 
e13 (94). Overexpression studies of recombinant CRH-R1d have demonstrated that, although this CRH-R1 variant retains agonist binding characteristics, it has significantly impaired G protein coupling and signaling properties. Given that most sites involved in GPCR signaling through posttranslational modifications and docking of signaling proteins are in the carboxyl-terminal tail, the possible retraction and distortion of this tail induced by the 14-amino acid sequence deletion would be expected to alter signaling and hence function. Similar splice variants arising from the same exon deletions have been described for other members of the B1 subfamily of GPCRs, such as the PTH-R (95) and the type II receptor for vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide receptor for vasoactive intestinal peptide (96). Analysis of the nucleotide sequence reveals that there are conserved splicing sites within the 7 TMD (site of exon deletion), shared among the members of this receptor family. The structural features of the receptor splice variants found in humans are shown in Fig. 1
.
|
The physiological relevance of the CRH-R1 mRNA splice variants has been dismissed as being a result of aberrant transcription. Characterization of the biological activity and signaling properties of some of these CRH-R1 variant receptor proteins is based on heterologous overexpression systems using recombinant protein expression and not native cells. This is due to a lack of suitable methods to demonstrate endogenous CRH-R1 variant expression and to study their physiological roles, if any, in mammalian tissues. Nevertheless, the complex pattern of CRH-R1 alternative splicing that is tissue-specific and physiological process-specific [i.e., expression of myometrial CRH-R1d at term of human pregnancy (90)] and affected by environmental stimuli [i.e., expression of CRH-R1g after UV irradiation (63)] suggests a functional role in modifying CRH actions in target tissues. It is conceivable that the presence of different isoforms could have a substantial influence on cellular response to CRH and CRH-like agonists. Regardless of whether or not these aberrant transcripts are significantly expressed as protein products, the dominant expression of the aberrant transcripts at the expense of the wild-type receptor at transcription would have the end result of reducing levels of functional receptor. Although our current knowledge of the mechanisms regulating CRH-R1 splicing and the specific function of distinct CRH-R1 variants is poor, emerging evidence points toward potentially important biological mechanisms. For example, we have identified a specific mechanism involving steroid hormones, which regulates the ratio of CRH-R1/R1ß mRNA expression in human myometrial smooth muscle cells during pregnancy. This may represent a mechanism for regulating tissue responsiveness to CRH (Fig. 2) (97). In this example, progesterone alters the transcription of the CRH-R1 gene in such a way that the predominant transcript encodes for CRH-R1, thus enhancing tissue responsiveness to CRH, an effect that is blocked by estrogen. Furthermore, some variants of CRH-R1, such as the CRH-R1d, fully retain the ability to bind agonist with high affinity although they are deficient in signaling. These receptor variants might act as "decoy receptors" capable of competing with the full-length receptors for agonist binding and absorbing CRH and CRH-like peptide bioactivity and therefore, change the efficiency of hormonal stimulation. Interestingly, in other receptor systems, such as the CT-R system, similar splice variants containing deletions in the 7 TMD, when coexpressed with the fully active CT-R variant, act as dominant negative regulators by forming heterooligomers within the cell. This process inhibits normal receptor expression at the cell surface, leading to a reduction in the signaling response (98). Similar interactions have been observed with the truncated forms of CRH-R1, e and h, which are capable of binding CRH and influencing tissue responsiveness to CRH. For example, in coexpression experiments, CRH-R1e attenuated and CRH-R1h amplified CRH-R1 signaling (99). These observations provide tantalizing, although far from conclusive, evidence suggesting that the regulation of transcription and splicing of the CRH-R1 receptor gene might play a major role in determining tissue responsiveness to CRH and UCNs. It should be remembered, however, that there is no evidence that these transcripts are translated into functional protein. This might not be a prerequisite, however, because the dominant expression of the aberrant transcripts at the expense of the wild-type receptor at transcription would have the end result of reducing levels of functional receptor.
|
):
|
b. Group 2.
The second group consists of mRNA variants missing exons 1, 2, 3, and 4, which are important for agonist binding and therefore appear functionally inert (R1e). Although it is difficult to attribute any direct role to individual members of this group, they might have important functional significance by modulating CRH-R1 activity.
c. Group 3.
Members of the third group have conserved the original reading frame of CRH-R1 up to the fifth exon, thus retaining an intact CRH-binding domain but having no TMDs. Two members of this group have been identified: CRH-R1j and CRH-R1h. CRH-R1j has exon 5 deleted, whereas CRH-R1h has an insertion of a cryptic exon between exons 4 and 5. If translated, these isoforms could potentially serve as soluble CRH-BPs or modulate agonist binding.
d. Group 4.
The fourth group consists of mRNA variants that have an intact CRH-binding domain and a variable number of TMDs (CRH-R1f, k, and m). Each of these transcripts contains a frame-shift that potentially alters their C terminus, raising questions about their potential for participation in signal transduction.
Studies on the promoter of the human CRH-R1 gene suggest that CRH-R1 agonists such as CRH and UCN-I can positively regulate CRH-R1 gene transcription (100) in agreement with several animal studies (101, 102, 103, 104). The hypothalamic PVN is a site of CRH-induced up-regulation of CRH-Rs. An example is the autoregulation of CRH biosynthesis in the PVN through up-regulation of CRH-R1, showing the mediation of positive effects on the amygdaloid CRH system (101). In rats, CRH-R1 mRNA in the PVN is increased after stress, and this response is attenuated by central CRH blockade. Elevated levels of central CRH may trigger CRH-R1 mRNA transcription in the PVN, hippocampus, and frontal cortex (102), suggesting a positive feedback of CRH on its own receptor, acting as a functional adaptation of the HPA axis in response to stress (103). These animal data are supported by studies on human cells and the human CRH-R1 promoter (100) in which a transcriptional positive feedback effect was shown to be dependent on activation of both protein kinase A (PKA) and protein kinase C (PKC) in the case of CRH, and PKC alone in the case of UCN. Collectively, the data suggest that the CRH-R1 gene is under the influence of both CRH and UCN, acting via distinct signaling pathways to create a positive feedback loop and regulate further the transcription of the receptor. However, this feedback mechanism requires further characterization because there is conflicting evidence suggesting positive and negative effects of CRH on rat anterior pituitary CRH-R1 expression (104, 105). Glucocorticoids are another important regulator of CRH-R1 gene expression because dexamethasone has been shown to act as a negative regulator of CRH-R1 mRNA expression in rodent anterior pituitary and PVN (106, 107, 108, 109).
Interestingly, the human as well as the rat CRH-R1 promoters are TATA-less, suggesting that Sp1 sites might play a crucial role for driving transcription because there are a high number of potential Sp1 elements clustered around the transcriptional start sites (100). Other members of the B1 family of GPCRs share this feature, including the promoters for the CT-R, the glucagon-like peptide receptor-1 and the vasointestinal peptide 1 receptor genes (100). The promoter region of the CRH-R1 also contains sites for Egr 2 (Krox-20) and YY1 (yin-yang 1) transcription factors (members of the zinc finger DNA binding transcription factors), which may also play a role in controlling transcription. The presence of a putative transcription response element, however, should not be taken as proof that a potential binding factor is a regulatory factor.
2. CRH-R2.
Interestingly, the CRH-R2 gene exhibits a completely different splicing pattern compared with CRH-R1, possibly relevant to its distinct role in mammalian physiology. Mammals express three known CRH-R2 variants: CRH-R2 and -R2ß are found in both human and rodents, and -R2
has so far been found only in the limbic regions of the human CNS (110, 111, 112), although genomic clones containing the CRH-R2 subtype have been identified in the olive baboon and chimpanzee. All three variant mRNAs are produced by the use of an alternate 5' exon 1 that splices onto a common set of downstream exons (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12), resulting in R2 variants, with identical transmembrane and C-terminus domains. These variants differ only in their N-terminal ECDs; CRH-R2 has 34 amino acids at the N terminus, which are replaced by 61 amino acids to form the CRH-R2ß or 20 amino acids to form the CRH-R2. The human CRH-R2 gene spans 50 kb and consists of 15 exons. Exon ß1a contains the 5'-untranslated region and the start codon for CRH-R2ß and, together with exon ß1b, contributes to the N-terminal ECD. Exons 1 and 1 contain the 5'-untranslated region and start codon for CRH-R2 and CRH-R2, respectively, which contributes to their unique N-terminal ECD. The remainder of the N terminus is encoded on exons 2–7, with exons 7–11 coding for the 7 TMDs and exon 12 coding for the intracellular C terminus, all of which are common to all known functional CRH-R2 receptors (113). The different N termini do not significantly alter agonist binding and signaling properties of the various CRH-related peptides, although the CRH-R2ß is about 10-fold more potent in second messenger activation compared with CRH-R2 or R2 (112). These variants, however, do exhibit significant differences in their tissue distribution. The CRH-R2 and the CRH-R2ß are expressed in both the brain and periphery (114), although CRH-R2 is mainly localized to the subcortical structures (114), whereas the CRH-R2 appears to be confined predominantly to the brain (112). In addition, both the CRH-R2 and CRH-R2ß variants are differentially expressed in heart, skeletal muscle, and myometrium (59, 77). In rodents, the CRH-R2 is the predominant CRH-R2 variant expressed in the rat brain (112, 114), whereas CRH-R2ß mRNA is widely expressed in peripheral tissues, with highest levels in the skeletal muscle, heart, and skin (67). Interestingly, the CRH-R2ß variant is primarily expressed peripherally in rodents, whereas the CRH-R2 is the predominant splice variant found in the periphery of humans. Given that different promoters regulate each CRH-R2 variant expression (see below), this diversity could be related to the regulation of expression at different tissues. The CRH-R2 gene appears to have diverged from CRH-R1 by duplication and then by increasing complexity to produce three subtypes with different pharmacology and differential expression. CRH-R2 is present in amphibians, whereas in rodents a second variant CRH-R2ß is also present, and in primates a third variant CRH-R2.
The arrangement of the CRH-R2 gene provides the potential for generating multiple alternate splice forms of mRNA (111, 112, 113). It is predicted that the CRH-R2ß pre-mRNA is differentially spliced, producing multiple alternate splice forms, and if any permutation of exons between ß1a and 2 occurs, at least 12 alternate splice forms can be produced, some with high levels of expression (113). Different types of aberrant mRNA splice variants have also been reported: 1) a truncated CRH-R2 mRNA isolated from rat amygdala (CRH-R2-tr), which encodes for the first three TMDs and a part of the fourth TMD of the CRH-R2 and binds CRH, but not UCN-I, with almost the same affinity as CRH-R2 (115); and 2) a soluble CRH-R2, in which exon 6 is deleted and translation of this variant produces a predicted 143-amino acid soluble protein. The translated protein includes the majority of the first ECD of the CRH-R2 followed by a unique 38-amino acid hydrophilic C terminus resulting from a frame-shift produced by deletion of exon 6. The soluble CRH-R2 variant has high levels of expression in the olfactory bulb, cerebral cortex, and midbrain regions. Experiments using recombinant proteins showed that soluble CRH-R2 protein inhibits cellular responses to CRH and UCN, supporting a potential role as a biological modulator of CRH and CRH-related peptides (116).
Three distinct promoters and differential splicing (113) control regulation of the human CRH-R2 gene expression. The arrangement of the 5'-flanking region of the gene is similar to that of the CRH-R1 gene in that it lacks a functional TATA or CCAAT box and contains several specificity protein 1 binding elements, which suggests that these elements constitute the minimal promoter. Each of the promoters contains some consensus regulatory sequences that provide some insights into CRH-R2 physiology. For example, the CRH-R2ß and CRH-R2 promoters contain consensus sequences for binding myogenic transcription factors, such as the myocyte-specific enhancer MEF-2, which may be involved in the regulation of expression in cardiac, skeletal, uterine, and smooth muscle. In contrast, the CRH-R2 promoter contains a putative regulatory element for the pituitary-specific factor Pit-1a, raising the possibility that the CRH-R2 is the CRH-R2 variant expressed in the pituitary (117). Putative glucocorticoid-responsive elements are also present in the CRH-R2 promoter, consistent with studies showing glucocorticoid regulation of CRH-R2 expression in the heart and brain (118, 119). This mechanism appears to be conserved across species because the mouse CRH-R2 5' flanking region contains 23 putative half-palindrome glucocorticoid response element sequences within its 2.4-kb sequence (120). This might explain the finding that hypothalamic murine CRH-R2 gene transcription is inhibited by glucocorticoid administration in vivo and enhanced by adrenalectomy. However, other studies have reported that in the VMH nucleus, the levels of CRH-R2 mRNA are up-regulated by corticosterone (119) and leptin administration (121), whereas, stressful stimuli such as starvation (119), repeated immobilization stress (122), and maternal deprivation (123) decrease the expression level of CRH-R2 mRNA in the rat VMH. The same study suggested that CRH-R2 gene expression is differentially regulated in different hypothalamic nuclei because neither corticosterone administration, starvation, nor adrenalectomy influenced the levels of CRH-R2 mRNA in the hypothalamic PVN (119). Clearly, additional studies are required to clarify these discrepancies and reveal the manner by which the CRH-R2 pathway is involved in physiological responses to stress in normal and transgenic mice models.
Despite the well-established role of CRH-Rs in human physiology and nosological states such as clinical depression, no striking abnormalities in CRH-R expression and/or function in human disease have been observed, with a few notable exceptions. In ACTH-secreting pituitary adenomas, a significant overexpression of the CRH-R1 mRNA has been reported (124), which may contribute to a disturbed receptor regulation. Also, in brains from suicide victims, the mRNA for cerebral cortical CRH-R1, but not CRH-R2, appears to be reduced, possibly secondary to sustained increase of CRH activity (125, 126), supporting the view that only the CRH-R1 subtype is aligned with mood disorders. The human placenta in patients with preeclampsia is another example of an organ where abnormal expression of CRH-R1 and -R2 has been reported and linked to an increased placental CRH production and abnormal regulation of the feto-placental blood flow (127, 128). However, in these cases it remains to be established whether abnormalities in CRH-R expression contribute to the pathogenesis of the disease or are secondary to the illness or the stressors associated with it.
|
IV. Agonist-CRH-R Interaction |
|---|
|
TopAbstractI. IntroductionII. CRH-R Agonists: the...III. CRH-R SubfamiliesIV. Agonist-CRH-R InteractionV. CRH-R Signaling...VI. Regulation of CRH-R...VII. ConclusionsReferences |
|---|
-helical CRH (9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41) (a peptide antagonist); however, at the CRH-R2 receptors, the binding affinity rank order is: human (h) UCN-I = hUCN-II > astressin = astressin2-B = antisauvagine-30 > hUCN-III > -helical CRH (9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41) > h/rCRH >> ovine (o) CRH. oCRH differs from its human homolog by eight amino acid residues and, in cellular systems expressing both types of CRH-R, it is the agonist of choice for the selective stimulation of CRH-R1, because it preferentially binds to CRH-R1. The binding constants of oCRH for CRH-R1 and -R2 differ by two orders of magnitude (129, 130). Recently, a CRH-R1-specific peptide agonist was generated, named cortagine ([Glu21,Ala40] [Svg1–12] x [h/rCRH14–30] x [Svg30–40]), by synthesis of chimeric peptides derived from h/rCRH, oCRH, and sauvagine (Svg; a frog CRH-related agonist) (131), and this might allow better characterization of CRH-R1 and -R2 function.
Characterization of the structure-function relationship of CRH and CRH-related agonists has revealed the presence of three main functional domains (132, 133, 134) (Fig. 4). The first domain (residues 1–16) is responsible for both binding and receptor activation. The second domain (residues 17–31) appears to function as a linker providing the appropriate spatial and conformational support for the two binding regions located in domains 1 and 3 and contains the CRH-BP binding site (stretch of amino acid residues 22–25, Ala-Arg-Ala-Glu, of h/rCRH representing the ARAE motif) (135). Finally, the third domain, consisting of residues 32–41, is important for receptor binding. Sequence analysis studies of all the members of the family of CRH-related agonists have revealed a number of differences between the CRH-R2 selective agonists, UCN-II and UCN-III, and the CRH-R nonselective agonists, CRH and UCN-I. A residue in the first domain, proline at position 11 (the numbering of residues is based on h/rCRH sequence), is found only in CRH-R2 selective peptides and might play an important role in determining receptor selectivity because substitution of Pro11 in the hUCN-II sequence with corresponding amino acids, found in the CRH-R nonselective agonists, decreased binding potency to CRH-R2 while increasing CRH-R1 activity. It is likely that the presence of this proline residue in the first domain alters the -helix structure of the peptide, because proline is the strongest modifier of -helix structure and a promoter of turn motifs. Consequently, the presence of Pro11 in the sequence of UCN-II and UCN-III may indicate that the -helix present in the first domain of the nonselective CRH-R peptides is modified through the introduction of a kink or turn motif, a modification that may be important in determining agonist selectivity (136). Indeed, circular dichroism spectroscopy studies support the view that the presence of Pro11 in this region decreases -helicity and impairs binding to CRH-R1 (137). Furthermore, in the third domain of the CRH-related peptides, CRH-R2 selective peptides contain alanine residues at positions 35 and 39, whereas CRH-R nonselective peptides contain an invariant arginine at position 35 and an acidic amino acid at position 39. Introducing proline at position 11 and alanine at positions 35 and 39 results in increased CRH-R2 selectivity in CRH-R nonselective peptides, mainly through the loss of CRH-R1 potency. Interestingly, unlike sauvagine and hUCN-I, this substitution in the h/rCRH sequence results in a loss of potency at both the CRH-R1 and -R2 (136), indicating that CRH requires additional substitutions to achieve substantial CRH-R2 selectivity.
|
-helical CRH (9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41)]. Additional modifications have produced a number of different antagonist peptides including astressin [cyclo(30–33)-[D-Phe12, Nle21,38, Glu30, Lys33]CRF-(12–41)], a high-affinity antagonist for both CRH-R receptors with enhanced biological stability (138) and no detectable agonist activity for the CRH-R1.
Mass spectrometric analysis of a soluble form of the N terminus of the human CRH-R1 yielded a 1:1 complex with ligand, and analysis of the disulfide bond arrangement revealed bonds between Cys30 and Cys54, Cys44 and Cys87, and Cys68 and Cys102 (139) (Fig. 5A). An identical arrangement was also found in the soluble N terminus of the mouse CRH-R2ß (140). This arrangement is similar to that of the N terminus of the PTH-R, suggesting a conserved structural motif in the N-terminal domain of the B1 family of GPCRs (141). Recent studies using nuclear magnetic resonance have provided valuable insights into the three-dimensional (3D) structure of the N-terminal ECD of the mouse CRH-R2ß (142). This technique has identified a short consensus repeat (SCR) in this domain, which is more commonly found in proteins of the complement system. This model proposes that the N terminus captures the C-terminal segment of the ligand, allowing the N terminus to penetrate into the TMD region of the receptor to initiate signaling. Key residues of the SCR in the ECD1 are conserved in the GPCR subfamily, suggesting the importance of this SCR fold in the ECD1s of this subfamily.
|
). Furthermore, the core is surrounded by a second layer of highly conserved residues, Thr69, Val80, and Arg82, and conservatively conserved residues, Thr63, Ser74, and Ile67. Other conserved residues, such as Pro72 and Pro83, might be important for ending the ß-strands, as well as Gly77, Asn106, and Gly107 located in the hinge regions of the two ß-sheets, which may be important for their relative orientation. Another cluster of conserved residues is present in the disordered loop between strands ß3 and ß4 (Gly92, Phe93, Asn94, and Thr96). In contrast, the disordered loop from residues 39–58 is highly variable in amino acid sequence.
Astressin B has been used in nuclear magnetic resonance chemical-shift perturbation experiments to identify the CRH-R2ß ligand binding site (142). The largest chemical-shift perturbations were observed in the segments comprising residues 67–69, 90–93, 102–103, and 112–116. These residues are clustered in the cleft region between the tip of the first ß-sheet and the edge of the "palm" of the second ß-sheet. The observed changes in the chemical shifts in the disordered loop region 85–98 suggest that folding occurs after ligand binding. Circular dichroism spectroscopy data support this view and show a conformational change toward a more structured N terminus upon ligand binding (140). Furthermore, the accumulated distribution of positive charges on the "back side" of the structure (Arg47, Arg82, Arg97) is indicative of orientation toward the negatively charged ECDs 2–4 and the transmembrane segment of CRH-R2ß. Based on these observations, it has been proposed that hormone binding and receptor activation occur in two steps. First, the ligand binds with its C-terminal segment to the solvent exposed binding site of the N terminus. In order for an agonist to elicit a signaling response, its N-terminal segment penetrates into the transmembrane segments of the CRH-R, producing activation of the receptor. In contrast, antagonists, like astressin, lacking the first 11 N-terminal residues critical for receptor activation cannot penetrate the transmembrane region and activate the receptor (Fig. 6).
|
of the rat CRH-R2 (143) revealed that the juxta-membrane receptor domain determines the selectivity of antisauvagine-30 [a synthetic CRH-R2 antagonist (144)], whereas the N-terminal-ECD contributes to selectivity of UCN-III, and both domains contribute to selectivity of UCN-II and astressin2-B [CRH-R2 antagonist (145)]. Therefore, ligands differ in the contribution of receptor domains to their selectivity, and CRH-R2-selective antagonists can bind the J-domain. Unlike the CRH-R1 receptor (see below), the CRH-R2 J-domain stabilizes affinity for agonists like UCN-II by about 30-fold and might act as a CRH-R2/CRH-R1 selectivity determinant. A further weak increase in CRH-R2 affinity for UCN-II is achieved by receptor G protein coupling. Overall, the current data suggest that the J-domain of the CRH-R2 receptor binds ligands more strongly than the J-domain of the CRH-R1 (at the R state).
The location of peptide ligand binding sites on the CRH-R1 receptor has also been investigated extensively by a number of studies using mutant and chimeric mammalian CRH-R1s (93, 146, 148, 149, 150, 151, 152). Current data suggest a model in which: 1) agonists such as CRH bind with moderate affinity to the N-domain (residues 1–118) (100 nM); 2) interaction with the J-domain (residues 110–415) weakly stabilizes CRH binding (<2-fold); and 3) G protein binding strongly stabilizes CRH-J-domain interaction (>1000-fold). Nonpeptide antagonist affinity and the full antagonist effect are provided predominantly if not exclusively by the J-domain. The isolated N-domain binds peptide agonist ligands with affinity similar to that seen in the low-affinity, G protein-uncoupled state (R state) of the whole receptor. In contrast, the isolated J-domain mediates full high-affinity binding of nonpeptide antagonists and nearly full efficacy receptor activation by peptide agonists, as demonstrated by activation of the J-domain by a tethered N-terminal CRH fragment (133). A number of different regions within the N-terminal domain appear to be crucial for the binding of CRH-R1 receptor agonists and peptide antagonists (Fig. 7). Examples are the region mapping to amino acids 43–50 and a second amino acid sequence extending from position 76 to 84 of the human CRH-R1 (93). Within the latter sequence, Arg76 and Asn81, but not Gly83, appear to be important for determining receptor affinity for CRH-R1 agonists. A third amino acid cassette extending from position 68–109 of mouse CRH-R1 located in close proximity to the first TMD has also been proposed to play an important role for high-affinity agonist binding. Furthermore, agonists like CRH require interactions with the EC loops and TMD of CRH-R1 for high-affinity binding. Within the J-domain of the CRH-R1, three regions have been mapped as being important for optimal agonist binding. Two of the regions are within the second ECD, amino acids 175–178 and His189 at the junction of EC2 and TM3, whereas the third region is at the junction of EC3 and TM5 and involves three amino acid residues, Val266, Tyr267, and Thr268. Also, studies in the rat CRH-R1 revealed that the third EC loop is involved in ligand binding, especially the cassette Tyr346-Asn348 located in close proximity with 7 TMD. In contrast, the region Glu336-Glu338 containing negatively charged amino acids of EC3, does not appear to participate in ligand binding. These studies raise the possibility that during ligand binding the polar part of this region in the third EC loop interacts directly with the polar N terminus of CRH to develop the CRH high-affinity binding site. They also suggest that different agonists require different binding domains within the receptor binding pocket; for example, although the three regions mentioned above also affect the binding of UCN-I and sauvagine, a fourth region in the EC3, Asp254, has been identified to be important for sauvagine but not CRH or UCN-I binding (149).
|
As mentioned previously, the N termini of the B1 family of GPCRs contain multiple Cys residues forming multiple disulfide bonds (141). The CRH-R contains six conserved Cys in its N-terminal domain and one Cys in each of the first and second EC loops (Cys188 and Cys258), respectively. Additionally, several other Cys residues are located in the TMDs (Cys128, Cys211, Cys233, and Cys364) and the first IC loop (Cys150). These disulfide bonds appear to be critical for ligand recognition as shown by site-directed mutagenesis experiments (157).
The CRH-R, like all members of the GPCR family, has the intrinsic ability to couple to heterotrimeric GDP/GTP-bound proteins, G proteins, an association that stabilizes the receptor in an active high-affinity conformation. A number of studies have shown that the binding of different agonists to specific CRH-R subtypes exhibits varying degrees of sensitivity to G protein coupling. In particular, the CRH-R2 high-affinity state and binding to agonists, such as sauvagine, CRH, and UCNs, is not significantly altered by the presence or absence of receptor-G protein interaction (RG and R states, respectively) (143). In contrast, although the CRH-R1 N-domain predominantly contributes to peptide agonist affinity, the R-G coupling dramatically enhances agonist affinity via an allosteric effect (146). It has been proposed that the CRH-R1 J-domain determines R-G coupling sensitivity, and the change of agonist affinity produced by this coupling probably reflects a change in receptor conformation. Therefore, it is possible that G protein coupling produces different conformational changes within the J-domain of the CRH-R2 compared with the CRH-R1 receptor. Nonpeptide CRH-R1 antagonists, which bind the J-domain, were able to block peptide agonist binding to RG, whereas the binding of peptide antagonists, predominantly to the N-domain, was unaffected by R-G coupling. A naturally occurring model of these structural/functional relationships is the human-specific CRH-R1 variant, R1ß, which has reduced binding affinity for CRH-R1 agonists although its N- and J-domains are intact (158). Impaired R-G coupling due to the presence of the 29-amino acid insert in the first IC loop probably results in reduced ligand affinity of the CRH-R1.
D. Receptor-G protein interactions: implications for signaling
Binding of an agonist to the receptor induces a conformational change and receptor activation that causes the G protein (G-subunit) to undergo an exchange of GDP (inactive state) for GTP (active state) (159, 160). Once GTP is bound to the G-subunit, it dissociates from the Gß dimer, allowing both species to activate a variety of signaling pathways. The ability of GPCRs to couple to different G protein heterotrimers, especially the G-subunit, is critical for activation of downstream signaling cascades and induction of diverse cellular responses. The intracellular pathway activated is largely determined by the interaction of individual GPCRs with different G proteins. Within mammalian cellular systems, more than 20 different G-subunits have been identified, which fall into four major classes: Gi/o, Gs, Gq, and G12 according to sequence homologies (161). Early studies investigating the effects of CRH on pituitary ACTH release demonstrated that activation of pituitary CRH-Rs leads to a potent cAMP response through stimulation of Gs proteins (162). The structural features of Gs necessary for GPCR coupling, nucleotide binding, and adenylyl cyclase stimulation are primarily contained within the -subunit (Gs), which also possesses an intrinsic GTP phosphohydrolase activity that limits the duration and strength of the signal (163).
It is now well accepted that most physiological functions of CRH in the CNS and the periphery involve CRH-R coupling to Gs proteins, although other G proteins undoubtedly play a role in some functions (164). Indeed, in certain tissues such as the testis and placenta (165, 166), the effects of CRH appear to be completely Gs-independent, despite adequate levels of endogenous Gs protein expression.
Characterization of recombinant CRH-R signaling properties in overexpression cellular systems, showed that both R1 and R2 primarily stimulate the adenylyl cyclase/cAMP pathway (45, 46) via coupling and activation of Gs proteins (90), including the XLs (extra large) protein (167), a large variant of Gs protein derived from the same GNAS1 gene that is highly expressed in neuroendocrine tissues with particularly high levels in the pituitary (168). Interestingly, these studies also demonstrated that the CRH-Rs are highly promiscuous and can activate different G-subunits, with an order of potency Gs
Go>Gq/11>Gi1/2>Gz. This is not surprising and, although most GPCRs interact only with one or a small subset of G proteins, there are many examples of GPCRs that couple to multiple G proteins (169, 170), and some couple to members from all four G protein families. Similar evidence was provided by the development of a reporter strain of the fission yeast Schizosaccharomyces pombe, in which the pheromone-response pathways were adapted to allow ligand-dependent signaling of heterologously expressed hCRH-R1 or hCRH-R2ß via either endogenous G proteins or yeast-mammalian chimeric G proteins (171). This approach confirmed that upon agonist activation, both CRH-R1 and -R2 can couple to multiple G proteins, including the G16 protein. The similar profile of G protein activation by R1 and R2 is not surprising, given that the two CRH-R subtypes share regions of considerable amino acid identity, especially between the fifth and sixth TMD (third IC loop), a region that is thought to be critical for G protein coupling and signal transduction. Furthermore, studies investigating the mechanisms regulating CRH-R1-G protein interaction have shown that the CRH-R-activated G proteins can be divided into two groups, depending on their functional response to regulatory intracellular mechanisms such as G protein-coupled receptor kinase (GRK)-induced desensitization (homologous desensitization; see Section VI) (172): 1) G proteins, including Gs and Gq/11, where the efficiency of the receptor-G protein coupling is modulated by desensitization; and 2) G proteins, such as the Gi, where coupling efficiency is not affected by homologous desensitization.
The multiple G protein interaction characteristic of CRH-R is also evident in native tissues such as cerebral cortex, myometrium, endometrium, placenta, and adrenal (61, 86, 166, 173, 174), indicating the enormous potential of CRH to regulate diverse signaling pathways. Interestingly, the pattern of G protein activation by endogenous CRH-Rs appears to be unique for each tissue and controlled by undefined mechanisms. Due to the complex nature and individual characteristics of mammalian tissues, the precise details of the coupling of the CRH-R to their cognate G protein are as yet unknown. Also, recent evidence suggests differences in the coupling characteristics of CRH-R/G proteins between different inbred animal strain models (175); for example, investigations of the effects of CRH on hippocampal neuronal excitability revealed that hippocampal CRH-Rs can activate Gs, Gq/11, and Gi in C57BL/6N mice, and only Gq/11 in BALB/c mice, suggesting genetic background influences on receptor/G protein coupling.
As mentioned previously, different agonists interact with specific binding domains within the receptor binding pocket, and this would probably lead to distinct active conformations of the CRH-R and different profiles of G protein activation. In vitro experiments using yeast reporter strains suggest that the agonist plays a major role in determining the G protein activation potency and profile for each CRH-R (171). Also, in mammalian native cells endogenously expressing CRH-R and cellular overexpression systems, CRH and UCN-I exhibit significant differences in the activation of certain G proteins and altered signaling properties (176, 177). For example, in HEK293 cells overexpressing hCRH-R1 and human smooth muscle cells, UCN-I-induced Gq-protein activation is significantly more potent compared with CRH, resulting in agonist-specific stimulation of extracellular signal regulated protein kinase (ERK1/2) cascade (177). These findings confirmed the critical role of CRH-R agonists as determinants of G protein coupling and signaling, in accordance with the "agonist-dependent signaling trafficking" hypothesis (178, 179). Other studies in native tissues demonstrated that the CRH-R-G protein coupling is not "static" but is rather dynamically regulated by physiological processes. For example, progression of human pregnancy toward term is associated with changes in myometrial smooth muscle tissue G protein coupled to CRH-R, and CRH-induced Gq-protein activation was evident at 39 wk but not at 33 wk gestation (176) (Fig. 8). This appears to be an important feature of the CRH-R that allows agonists such as CRH to activate different signaling cascades during the different stages of pregnancy and labor and thus play an important role in the transition of the human uterus from a state of relaxation to one of increased contractility and active labor (176). Therefore, it appears that a revised hypothesis, which should include the agonist, receptor subtype, and cell type as the critical determinants of "signaling trafficking", would more accurately represent the CRH-R/G protein interactions and downstream signaling pathways activation.
|
and specific recognition of the Gs protein following agonist binding (181). Furthermore, other amino acids within IC3 appear to be important for efficient receptor-G protein interaction. We identified Ser301 as an important residue for interaction with Gs, Go, Gq/11, and Gi1/2 (182). Studies using mutant receptors showed that the nature of the residue present in position 301 plays a significant role in determining the G protein activation efficiency of the hCRH-R1, either through stabilization of the amphipathic -helix of the IC3 or direct amino acid to amino acid interactions between CRH-R1 and G proteins. Go proteins appeared to be the most sensitive to amino acid substitution at this position, whereas the weakly activated Gi was the least. These studies also demonstrated the preference of Gs protein for acidic, but not charged, amino acid residues at position 301 to achieve full activation through the interaction with the receptor.
Another important aspect of CRH-R interactions with G proteins is the intracellular mechanisms regulating its ability of the CRH-R1 to switch between different G proteins and signaling cascades. There is very little evidence relating to this, however, but it is conceivable that tissue-specific mechanisms are involved, based on the unique profiles of activated G proteins seen in various tissues (61, 86, 164, 173, 174). Evidence from other GPCRs suggests that receptor phosphorylation by intracellular protein kinases might be one such important mechanism. Phosphorylation by PKA of the ß2-adrenergic receptor switches its coupling from Gs to Gi (183). A similar self-regulatory mechanism regulates CRH-R1 coupling to G proteins, and Gs-induced PKA activation results in CRH-R1 phosphorylation and selective impairment of CRH-R1/Gq protein coupling, suggesting that phosphorylation of Ser301 may prevent optimal interaction of the CRH-R1 with specific G proteins, such as Gq protein (182).
|
V. CRH-R Signaling Characteristics |
|---|
|
TopAbstractI. IntroductionII. CRH-R Agonists: the...III. CRH-R SubfamiliesIV. Agonist-CRH-R InteractionV. CRH-R Signaling...VI. Regulation of CRH-R...VII. ConclusionsReferences |
|---|
s protein. This pathway initiates intracellular events both in the cytoplasm, resulting in the acute posttranslational modification of target proteins by PKA, and in the nucleus at the level of gene transcription regulation by cAMP response element-binding (CREB) proteins (184, 185). Pharmacological agents have proved useful in dissecting the contribution of the cAMP/PKA/CREB signaling pathway in mediating the biological actions of CRH and the UCNs in different systems (85, 164, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196) (Table 1). A further level of complexity is provided by accumulating evidence that implicates other signaling molecules in the amplification or modification of these cAMP/PKA-mediated responses. Examples of this include activation of membrane-bound guanylyl cyclase activity and increased cGMP production in smooth muscle cells (174), stimulation of the nuclear factor-
B pathway in mouse thymocytes (198), phosphorylation of glycogen synthase kinase-3 in CNS neurons (199), suppression of the activity of slow Ca2+-activated K+ current [I(sAHP)] in CA1 hippocampal pyramidal neurons (200), and increased tyrosine hydroxylase phosphorylation in rat adrenal PC12 cells (201).
|
Few studies have investigated the transcriptional response of CRH-R1 signaling at the level of the genome. One report (207) using oligonucleotide microarrays in At-20 corticotroph cells, identified many novel CRH/CRH-R1, and potentially cAMP, responsive genes including transcription factors such as the cAMP-responsive element modulator, nuclear factor regulated by IL-3 and Jun-B, secreted peptides such as choleystokinin, and signaling modulating proteins such as receptor (calcitonin) activity modifying protein 3, cAMP-specific phosphodiesterase 4B, the regulatory subunit phosphatidylinositol 3-kinase p85, and regulator of G protein signaling 2 that potentially can attenuate CRH signaling through negative feedback interactions. Also, in a more focused approach, Sirianni et al. (208, 209) employed oligonucleotide microarrays in human fetal zone and in definitive/transitional zone adrenal cells and demonstrated that CRH and UCN-I, acting via the CRH-R1 receptor, can directly induce the expression of various enzymes involved in adrenal dehydroepiandrosterone sulfate and cortisol production. These include steroidogenic acute regulatory protein, cholesterol side chain cleavage (CYP11A), 17-hydroxylase (CYP17), 21-hydroxylase (CYP21), dehydroepiandrosterone sulfotransferase (SULT2A1), 3ß-hydroxysteroid dehydrogenase type II (HSD3B2), 11ß-hydroxylase (CYP11B1). Significantly, both studies in the corticotrophs and adrenal cells also demonstrated the ability of CRH to up-regulate the expression of CRH-R1 gene (207, 208).
B. cAMP-independent signaling pathways: CRH-Rs and activation of MAPKs
In some studies, pharmacological inhibition of the cAMP/PKA pathway failed to abolish the biological effects of CRH and CRH-related agonists, suggesting that these agonists and their receptors can induce cellular events through alternative signaling pathways. An example of the latter is the tissue-specific regulation of the nuclear factor-B pathway in human epidermal keratinocytes and pituitary corticotroph cells where it is involved in the activation of the POMC gene (210, 211). It is now well established that the CRH-Rs can activate a plethora of intracellular pathways both in vivo and in vitro, in agreement with the data on multiple G protein activation. These include PKC, PKB/Akt, ERK, and p38 MAPK, as well as other important signaling molecules, such as Ca2+, nitric oxide synthase (NOS), guanylyl cyclase, prostaglandins, RhoA/ Rho kinase, Fas and Fas ligand (212, 213, 214, 215, 216, 217, 218, 219).
A number of signaling molecules mediating the biological functions of CRH-Rs in the CNS and the periphery have attracted particular attention, especially the family of MAPK enzymes, in particular ERK and p38 MAPK. Both enzymes are stimulated by agonist-activated CRH-R1 or CRH-R2 in cells expressing either endogenous or recombinant CRH-Rs (76, 177, 202, 206, 212, 219, 220, 221). This signaling pathway appears to mediate important physiological functions of CRH and CRH-related agonists such as cardioprotection against ischemia reperfusion injury (76), the behavioral and memory adaptation to stress (222), neuroprotection (189, 223), vasodilatation (224), and smooth muscle contractility (219). Furthermore, ERK mediates the CRH-induced activation of Nur transcription factors and induction of POMC in AtT-20 cells (206) and the CRH-induced suppression of caspase-dependent apoptosis and cytotoxicity in Y79 retinoblastoma cells (225), whereas p38 MAPK is involved in CRH inhibitory effects on IL-18 expression in human keratinocytes (226). Interestingly, studies on the G proteins and signaling molecules involved downstream of CRH-Rs suggest unique tissue-specific features. For example, in brain and neuronal cells such as AtT-20 or Y79 neuroblastoma cells, agonist-induced activation of CRH-Rs and ERK phosphorylation involves the Gs protein-adenylyl cyclase pathway (206, 225), whereas in uterine smooth muscle cells this effect appears to be exerted primarily, but not exclusively, via activation of the Gq-IP3-PKC pathway (177). In uterine smooth muscle, the intracellular signaling pathways appear quite complex because activation of the Gs protein-adenylyl cyclase-PKA pathway attenuates agonist-induced ERK activation through PKA-induced phosphorylation of the CRH-R1 at position Ser301, a posttranslational modification event that inhibits maximal coupling of CRH-R with Gq protein (182) and allows a CRH-R1 signaling switch. These events are likely to have significant physiological significance, because ERK activation plays a major role in cell proliferation, and the cross-talk between the adenylyl cyclase/PKA and the ERK cascades involving PKA-mediated regulation of various downstream intracellular molecules is well established (227, 228). For example, CRH activation of the CRH-R1-adenylyl cyclase-PKA pathway in the Ishikawa human endometrial adenocarcinoma cell line has been shown to inhibit cell growth and proliferation (191). Although not examined in this study, it is conceivable that this effect is mediated via inhibition of ERK activity. Another example of the potential physiological importance of CRH-R1 signal switching is the human pregnant myometrium. At term, UCN-I induces ERK activation and possibly enhances myometrial contractility (177, 229), because ERK has been proposed to be involved in the regulation of myometrial contractility in rats (230). On the other hand, human pregnancy is associated with increased myometrial PKA activity (40), which might provide a mechanism for preventing "inappropriate" ERK activation by CRH-like agonists to maintain uterine quiescence before the timely onset of labor. This view is supported by our studies of CRH-R-G protein coupling during different stages of pregnancy, which have shown activation of Gq proteins by UCN in term (39 wk gestation) but not preterm (33 wk gestation), myometrial tissue (Fig. 8), coincidental with a reduction in the ability of CRH-R agonists to activate Gs protein (176).
The unique tissue-specific requirement for particular G protein activation to stimulate ERK activity is closely determined by the ability of individual CRH-R agonists to activate the necessary G proteins. Our own studies have shown that in native myometrial cells UCN-I, but not CRH, can trigger ERK activation because only UCN-I induces CRH-R-Gq protein coupling and translocation of PKC with sufficient potency to activate this pathway (177). In contrast, in brain tissue, where ERK phosphorylation and activation are primarily dependent on Gs protein-PKA activation, both CRH and UCN-I are capable of activating this cascade (189). This finding further supports the hypothesis of agonist, receptor subtype, and cell type determinants of signaling trafficking.
Intriguingly, the CRH-R-ERK interaction appears to be extremely versatile and depends upon activation of multiple signaling pathways, a common feature of many GPCRs that regulate ERK activity. This probably reflects the crucial role of this signaling cascade in mediating the biological effects of CRH in different cellular systems. In addition to the Gq-IP3-PKC pathway, other signaling molecules such as Gi and Go proteins, phosphatidylinositol-3-OH kinase, MAPK kinase 1, Raf-1 kinase, tyrosine kinases, and possibly intracellular Ca2+ have all been implicated in CRH-R-induced ERK activation (220), highlighting the complexity of these interactions.
C. CRH-Rs and the regulation of the NO/cGMP signaling pathway
Another important signaling pathway that is regulated by CRH and CRH-related agonists in various physiological systems is the nitric oxide (NO)/cGMP pathway, a major signaling cascade in the control of vascular tone (231). In a number of different cellular systems, CRH and CRH-related peptides can modulate the expression and activity of NOS, the enzyme that is primarily responsible for intracellular formation of NO, and the induction of intracellular events involving activation of the soluble form of guanylyl cyclase and production of the second messenger cGMP. In uterine smooth muscle cells, activation of CRH-R1 leads to up-regulation of the constitutive (endothelial and brain), but not inducible, NOS through a Gs protein-PKA independent pathway (174). Similar CRH-R1-mediated interactions have been observed in human placenta (128). In this tissue, however, this effect is mediated via CRH-R2 specific agonists such as UCN II, possibly reflecting differences in the relative expression levels/accessibility between the CRH-R subtypes in the two cellular systems. This placental signaling pathway appears to play a major role in the CRH-induced control of vascular tone (232), and abnormal down-regulation of placental CRH-R expression has been implicated in the increased vascular resistance of this organ in women with preeclampsia (127, 128). Interestingly, in other cellular systems, CRH differentially regulates indicible NOS (iNOS) expression, suggesting a more complex relationship and highlighting the tissue-specific effects of CRH-R agonists. Examples are H5V murine endothelioma cells, which express both CRH-R subtypes and in which CRH attenuates cytokine-stimulated iNOS protein expression, an effect mediated via CRH-R1 receptors, and HUVEC cells that express only CRH-R2 and in which CRH potentiates cytokine-induced iNOS expression (214).
CRH and CRH-like agonists can also acutely augment NOS and soluble guanylyl cyclase (sGC) activity in a NO-independent pathway, resulting in increased intracellular levels of cGMP (128, 174). This pathway also appears to be important in CRH and UCN-induced relaxation of placental vasculature and peripheral arteries, a process that involves release of NO with subsequent activation of Ca2+-activated K+ channels in vascular smooth muscle cells via a cGMP-dependent mechanism (224, 234). Acute regulation of NO and/or sGC/cGMP signaling pathways has been described in the pituitary involving not just CRH, but a number of adenylyl cyclase-activating agonists (217). These agonists stimulate cGMP production through PKA-induced phosphorylation of Ser107-Ser108 N-terminal residues of the 1-sGC subunit that most likely stabilizes the NO/1ß1 sGC heterodimer complex (236). Furthermore, in uterine smooth muscle cells, CRH can also potentiate intracellular cGMP production through a distinct pathway involving enhancement of the membrane-bound form of guanylyl cyclase activity via a partially PKA-dependent mechanism (128).
|
VI. Regulation of CRH-R Functional Activity |
|---|
|
TopAbstractI. IntroductionII. CRH-R Agonists: the...III. CRH-R SubfamiliesIV. Agonist-CRH-R InteractionV. CRH-R Signaling...VI. Regulation of CRH-R...VII. ConclusionsReferences |
|---|
Most studies agree that homologous desensitization of CRH-R1 is a PKA-independent process (240, 244), despite the fact that the CRH-R1 sequence contains a putative PKA phosphorylation site at position Ser301 (40). Upon activation by the Gs protein-cAMP pathway, PKA can indeed phosphorylate the CRH-R1, and this modification appears to be important for specific G protein coupling and signaling selectivity (182). The same might be true for the CRH-R2 because both CRH-R subtypes have identical potential PKA phosphorylation sites. Studies in different cellular systems (HEK293 and Y79 neuroblastoma cells) have also identified multiple GRKs involved in CRH-R1-phosphorylation and homologous desensitization: GRK3 appears to be the major "cytosolic" GRK isoform, and GRK6 the main "membrane-bound" GRK isoform. GRK3 requires Gß-subunits for its recruitment to the plasma membrane and association with the CRH-R1; by contrast, GRK6 is able to interact with the CRH-R1 in a Gß-subunit-independent manner, due to its constitutive association with the plasma membrane (245). However, recent studies suggest that in cellular systems where GRK3 is not present (such as AtT-20 corticotroph cells), GRK2 participates in homologous CRH-R1 desensitization (246). The cAMP/PKA pathway may also have a role in this mechanism by activating GRK2 through phosphorylation. Putative sites of GRK-mediated phosphorylation of CRH-R1 have been searched within the distal portion of the cytoplasmic tail of the CRH-R1, which contains a cluster of Ser/Thr residues (Ser396-Ser405). Site-directed mutagenesis studies identified Thr399 as a GRK-phospho-acceptor residue (240) important for mediating CRH-R1 homologous desensitization. Interestingly, in some biological systems such as the human retinoblastoma Y79 cells, the CRH-R1 appears to control its own desensitization rate by up-regulating GRK3 mRNA levels (235). This effect appears to be directed specifically toward GRK3, because GRK2 levels are not affected, and during prolonged exposure to high CRH it might act as a cellular negative feedback mechanism to maximize CRH-R1 desensitization. This phenomenon also appears to be agonist-dependent because in the same cellular setting only CRH, but not UCN-I, induced GRK3 up-regulation.
Most studies investigating the role of homologous desensitization on CRH-R signaling have focused on the activation of adenylyl cyclase, although the CRH-R can potentially activate multiple signaling cascades, in line with the concept of GPCR signaling diversity as a result of different ternary complexes and active conformational states of the receptor (233). Preliminary studies in a CRH-R1 overexpression cellular system (172) suggest that homologous desensitization primarily attenuates Gs and Gq/11-driven signaling cascades. In contrast, CRH-R1 receptor states that induce Gi protein activation are not susceptible to desensitization, either because the important Ser/Thr are not accessible for phosphorylation or potential phosphorylation does not interfere with the Gi protein coupling. This might represent a regulatory mechanism that allows a more rapid decline of some CRH-R1 stimulatory effects.
GRK-induced phosphorylation of the agonist-activated receptor at specific Ser/Thr residues interferes with the G protein coupling of the GPCRs and facilitates the interaction of the receptor with intracellular proteins that maintain the inactive state of the receptor and favor its internalization (238). For many but not all GPCRs, this process involves receptor interaction with members of the arrestin family of proteins (197). The binary complex formed between the phosphorylated GPCR and arrestin initiates two important intracellular processes, receptor uncoupling and internalization, that are involved in both the desensitization and the recovery of cellular responses. In HEK293 cells overexpressing CRH-R1 receptors, ß-arrestin appears to be involved in CRH-R1 desensitization and internalization (240). Once the receptor is activated by agonist binding, the ß-arrestin rapidly translocates to the plasma membrane in close proximity to the CRH-R1. Phosphorylation of the CRH-R1 by GRK and intact phosphorylation sites within the IC3 and the C terminus are required for efficient ß-arrestin recruitment (186). Although the internalization characteristics of the CRH-R1 have not yet been characterized in detail, some preliminary evidence suggests the involvement of clathrin-coated pits in CRH-R1 internalization (153, 186). However, under different experimental conditions, CRH-R1 internalization appears to be independent of the degree of ß-arrestin recruitment and/or receptor phosphorylation (186), revealing a potential versatility of the CRH-R1 internalization mechanisms. Furthermore, recent data suggest a more complex relationship between agonist-CRH-R activation-signal generation and CRH-R1 internalization. Astressin, an amino-terminal truncated analog of CRH with high-affinity binding to the N terminus of the CRH-R1, which is thought to act as a neutral competitive antagonist, is capable of inducing CRH-R1 internalization, despite being unable to stimulate CRH-R1 signaling (153). This finding might be of considerable significance for the design of CRH-R antagonists for specific disorders because it would allow suppression of receptor signaling by inducing its internalization. Intriguingly, CRH and astressin employ distinct internalization pathways. Binding of CRH to CRH-R1 induces phosphorylation, ß-arrestin recruitment, and receptor internalization most likely through clathrin-coated pits, whereas binding of astressin fails to induce receptor phosphorylation or ß-arrestin recruitment. Instead, receptor endocytosis occurs through a pathway involving sequestration into intracellular compartments other than clathrin-coated pits and caveolae. To induce CRH-R1 internalization, astressin must interact with both the N terminus and the J-domain of the receptor. These data raise the possibility that in the CRH-R1 the two processes of receptor activation and signaling and receptor internalization might not be closely related and demonstrate that under certain conditions (e.g., antagonist binding), the CRH-R1 can adopt distinct active conformations important for specific functions such as receptor internalization.
The potential role of PKC has also been investigated in CRH-R homologous and heterologous desensitization and internalization. Most studies agree that PKC activation is not involved in homologous CRH-R1 desensitization and internalization (186), although in some cellular systems, CRH actions are modulated by PKC, and accumulating evidence suggests that the CRH-R1 is indeed a target of PKC-induced phosphorylation. For example, in Y79 human neuroblastoma cells, PKC is involved in the heterologous, but not the homologous, desensitization of the CRH-induced cAMP response (147). Furthermore, oxytocin-induced PKC activation in human pregnant myometrium at term inhibits CRH-R activity (91). The latter experimental paradigm provided evidence that some, but not all, CRH-R isoforms are sensitive to oxytocin-induced PKC activation in human term myometrium. Data from our laboratory suggest that only the human-specific CRH-R1ß variant appears to be susceptible to PKC-induced desensitization resulting in the endocytosis of the CRH-R1ß variant in a ß-arrestin independent manner (D. Markovic, N. Papadopoulou, T. Teli, H. Randeva, M. A. Levine, E. W. Hillhouse, D. K. Grammatopoulos, submitted for publication). Furthermore, the presence of Ser408 in the distal part of the CRH-R1 C-tail appears to confer its resistance to PKC-induced desensitization and internalization because replacement of Ser408 rendered the CRH-R1 susceptible to PKC-induced desensitization and internalization. Variable usage of specific phospho-acceptor sites by protein kinases is a phenomenon described for other GPCRs (75). It is possible that PKC initially targets Ser408 as the primary phospho-acceptor site and phosphorylation of this residue prevents receptor desensitization and internalization. Lack of this residue may lead PKC to target other putative phosphorylation sites and initiate receptor desensitization and internalization, directly or indirectly via trans-activation of specific GRK isoforms or other protein-protein interactions. This might represent an important mechanism for functional regulation of CRH signaling in target cells. An overview of these intracellular mechanisms targeting the CRH-R1 is presented in Fig. 9.
|
|
VII. Conclusions |
|---|
|
TopAbstractI. IntroductionII. CRH-R Agonists: the...III. CRH-R SubfamiliesIV. Agonist-CRH-R InteractionV. CRH-R Signaling...VI. Regulation of CRH-R...VII. ConclusionsReferences |
|---|
|
Acknowledgments |
|---|
|
Footnotes |
|---|
First Published Online February 16, 2006
Abbreviations: CNS, Central nervous system; CREB, cAMP response element-binding; CRF, corticotropin-releasing factor; CRH-BP, CRH binding protein; CRH-R, CRH receptor(s); CT-R, calcitonin receptor; 3D, three-dimensional; EC, extracellular; ECD, EC domain; GPCR, G protein-coupled receptor; GRK, G protein-coupled receptor kinase; h, human; HPA, hypothalamo-pituitary-adrenal; h/rCRH, human/rat CRH; IC, intracellular; iNOS, indicible NOS; LD, linkage disequilibrium; o, ovine; NO, nitric oxide; NOS, NO synthase; PKA, protein kinase A; PKC, protein kinase C; PTH-R, PTH receptor; PVN, paraventricular nucleus; SCR, short consensus repeat; sGC, soluble guanylyl cyclase; TMD, transmembrane domain; UCN, urocortin; VMH, ventromedial hypothalamic.
|
References |
|---|
|
TopAbstractI. IntroductionII. CRH-R Agonists: the...III. CRH-R SubfamiliesIV. Agonist-CRH-R InteractionV. CRH-R Signaling...VI. Regulation of CRH-R...VII. ConclusionsReferences |
|---|
(CRH-1) and the CRH-C variant receptor. J Clin Endocrinol Metab 83:1376–1379e13 isoform of the calcitonin receptor forms a six transmembrane domain receptor with dominant negative effects on receptor surface expression and signalling. Mol Endocrinol 19:2132–2144e13 transcript of the rabbit calcitonin receptor dimerizes with the C1a isoform and inhibits its surface expression. J Biol Chem 278:23085–23093 receptor. Mol Endocrinol 12:1077–1085 (CRF(2) -tr) in the rat brain. Biochem Biophys Res Commun 280:553–557[CrossRef][Medline] corticotropin-releasing factor (CRF) receptor binds ligands and modulates their activity. Proc Natl Acad Sci USA 102:2620–2625 gene: isolation, distribution, pharmacological characterization and regulation by stress and glucocorticoids. Mol Endocrinol 19:441–458 in human preeclamptic and growth-restricted placentas. J Clin Endocrinol Metab 88:363–370-subunit mutations and the role of genomic imprinting. Endocr Rev 22:675–705 (s), the extra-large variant of the stimulatory G protein -subunit. Mol Endocrinol 16:1912–1919-subunit XLs I. Tissue distribution and subcellular localization. J Biol Chem 275:33622–33632 and R2ß CRH receptor subtypes and stimulation of Gq-proteins. Mol Endocrinol 14:2076–2091 structural domains critical for Gs-protein activation: evidence for distinct receptor active conformations associated with CRH and urocortin binding. Rev Clin Pharmacol Pharmacokinet 18:142–143B by corticotropin-releasing hormone in mouse thymocytes. Mol Endocrinol 16:2561–2570 receptors regulate phosphorylation of calcium/cyclic adenosine 3',5'-monophosphate response element-binding protein and activation of p42/p44 mitogen-activated protein kinase. Endocrinology 140:1525–1536B in human epidermal keratinocytes. J Endocrinol 181:R1–R7B participates in the corticotropin-releasing, hormone-induced regulation of the pituitary proopiomelanocortin gene. J Biol Chem 279:10837–10840q. J Biol Chem 273:18023–18027-induced rat puerperal uterine contraction. Endocrinology 138:3103–3111 1 soluble guanylyl cyclase enhances nitric oxide-dependent cyclic guanosine 5'-monophosphate production in pituitary cells. Mol Endocrinol 18:458–470 signaling: structural determinants for G protein-coupled receptor kinase-mediated phosphorylation and agonist-mediated desensitization. Mol Endocrinol 19:474–490This article has been cited by other articles:
 |
|
 |
|
  M. Larauche, G. Gourcerol, L. Wang, K. Pambukchian, S. Brunnhuber, D. W. Adelson, J. Rivier, M. Million, and Y. Tache Cortagine, a CRF1 agonist, induces stresslike alterations of colonic function and visceral hypersensitivity in rodents primarily through peripheral pathways Am J Physiol Gastrointest Liver Physiol, July 1, 2009; 297(1): G215 - G227. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hahn, F. W. Hopf, and A. Bonci Chronic Cocaine Enhances Corticotropin-Releasing Factor-Dependent Potentiation of Excitatory Transmission in Ventral Tegmental Area Dopamine Neurons J. Neurosci., May 20, 2009; 29(20): 6535 - 6544. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Gkountelias, T. Tselios, M. Venihaki, G. Deraos, I. Lazaridis, O. Rassouli, A. Gravanis, and G. Liapakis Alanine Scanning Mutagenesis of the Second Extracellular Loop of Type 1 Corticotropin-Releasing Factor Receptor Revealed Residues Critical for Peptide Binding Mol. Pharmacol., April 1, 2009; 75(4): 793 - 800. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Ben-Shlomo, C. Zhou, O. Pichurin, V. Chesnokova, N.-A. Liu, M. D. Culler, and S. Melmed Constitutive Somatostatin Receptor Activity Determines Tonic Pituitary Cell Response Mol. Endocrinol., March 1, 2009; 23(3): 337 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. F Seasholtz, M. Ohman, A. Wardani, and R. C Thompson Corticotropin-releasing hormone receptor expression and functional signaling in murine gonadotrope-like cells J. Endocrinol., February 1, 2009; 200(2): 223 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. J. Westphal, R. T. Evans, and A. F. Seasholtz Novel Expression of Type 1 Corticotropin-Releasing Hormone Receptor in Multiple Endocrine Cell Types in the Murine Anterior Pituitary Endocrinology, January 1, 2009; 150(1): 260 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Rivier Urocortin 1 Inhibits Rat Leydig Cell Function Endocrinology, December 1, 2008; 149(12): 6425 - 6432. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Markovic, H. Lehnert, M. A. Levine, and D. K. Grammatopoulos Structural Determinants Critical for Localization and Signaling within the Seventh Transmembrane Domain of the Type 1 Corticotropin Releasing Hormone Receptor: Lessons from the Receptor Variant R1d Mol. Endocrinol., November 1, 2008; 22(11): 2505 - 2519. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Gao, C. Lu, C. Xu, Y. Tao, B. Cong, and X. Ni Differential Regulation of Prostaglandin Production Mediated by Corticotropin-Releasing Hormone Receptor Type 1 and Type 2 in Cultured Human Placental Trophoblasts Endocrinology, June 1, 2008; 149(6): 2866 - 2876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. Varela, T. Hermosilla, and G. W. Zamponi Making the T-Type Even Tinier: Corticotropin-Releasing Factor-Mediated Inhibition of Low-Voltage-Activated Calcium Channel Activity Mol. Pharmacol., June 1, 2008; 73(6): 1589 - 1591. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-M. O'Carroll, G. M Howell, E. M Roberts, and S. J Lolait Vasopressin potentiates corticotropin-releasing hormone-induced insulin release from mouse pancreatic {beta}-cells J. Endocrinol., May 1, 2008; 197(2): 231 - 239. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Markovic, A. Punn, H. Lehnert, and D. K. Grammatopoulos Intracellular Mechanisms Regulating Corticotropin-Releasing Hormone Receptor-2{beta} Endocytosis and Interaction with Extracellularly Regulated Kinase 1/2 and p38 Mitogen-Activated Protein Kinase Signaling Cascades Mol. Endocrinol., March 1, 2008; 22(3): 689 - 706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Orozco-Cabal, J. Liu, S. Pollandt, K. Schmidt, P. Shinnick-Gallagher, and J. P. Gallagher Dopamine and Corticotropin-Releasing Factor Synergistically Alter Basolateral Amygdala-to-Medial Prefrontal Cortex Synaptic Transmission: Functional Switch after Chronic Cocaine Administration J. Neurosci., January 9, 2008; 28(2): 529 - 542. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Dan Jin, Ping He, Xingji You, Xiaoyan Zhu, Ling Dai, Qian He, Chunmin Liu, Ning Hui, Jinyan Sha, and Xin Ni Expression of Corticotropin-Releasing Hormone Receptor Type 1 and Type 2 in Human Pregnant Myometrium Reproductive Sciences, September 1, 2007; 14(6): 568 - 577. [Abstract] [PDF]
|
|
|
|
|
|
L. Gao, P. He, J. Sha, C. Liu, L. Dai, N. Hui, and X. Ni Corticotropin-Releasing Hormone Receptor Type 1 and Type 2 Mediate Differential Effects on 15-Hydroxy Prostaglandin Dehydrogenase Expression in Cultured Human Chorion Trophoblasts Endocrinology, August 1, 2007; 148(8): 3645 - 3654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Markovic, M. Vatish, M. Gu, D. Slater, R. Newton, H. Lehnert, and D. K. Grammatopoulos The Onset of Labor Alters Corticotropin-Releasing Hormone Type 1 Receptor Variant Expression in Human Myometrium: Putative Role of Interleukin-1{beta} Endocrinology, July 1, 2007; 148(7): 3205 - 3213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. A. Rissman, K.-F. Lee, W. Vale, and P. E. Sawchenko Corticotropin-Releasing Factor Receptors Differentially Regulate Stress-Induced Tau Phosphorylation J. Neurosci., June 13, 2007; 27(24): 6552 - 6562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. O Huising, L. M van der Aa, J. R Metz, A. de Fatima Mazon, B M L. V.-v. Kemenade, and G. Flik Corticotropin-releasing factor (CRF) and CRF-binding protein expression in and release from the head kidney of common carp: evolutionary conservation of the adrenal CRF system J. Endocrinol., June 1, 2007; 193(3): 349 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. V. Wu, P.-q. Yuan, L. Wang, Y. L. Peng, C.-Y. Chen, and Y. Tache Identification and Characterization of Multiple Corticotropin-Releasing Factor Type 2 Receptor Isoforms in the Rat Esophagus Endocrinology, April 1, 2007; 148(4): 1675 - 1687. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Smith Parturition N. Engl. J. Med., January 18, 2007; 356(3): 271 - 283. [Full Text] [PDF]
|
|
|
|
|
|
A. Punn, M. A. Levine, and D. K. Grammatopoulos Identification of Signaling Molecules Mediating Corticotropin-Releasing Hormone-R1{alpha}-Mitogen-Activated Protein Kinase (MAPK) Interactions: The Critical Role of Phosphatidylinositol 3-Kinase in Regulating ERK1/2 But Not p38 MAPK Activation Mol. Endocrinol., December 1, 2006; 20(12): 3179 - 3195. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
